Clinical Trial Update: A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 pilot trial evaluating regulatory T-cell suppression with Ontak in metastatic pancreatic cancer has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• ONTAK (denileukin diftitox)

Snippet

Sponsor: Loyola University | Conditions: Metastatic Pancreatic Cancer | Phase 2 | Status: TERMINATED | Results posted: 2016-08-24